2 Seventy Bio Inc (TSVT)

May 15, 2025

Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

May 15, 2025

May 13, 2025

Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

May 13, 2025

May 07, 2025

Earnings call transcript: Nuvation Bio Q1 2025 sees strategic focus amid EPS miss - Investing.com India

May 07, 2025

May 07, 2025

2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire

May 07, 2025

May 02, 2025

Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $5.60 - Defense World

May 02, 2025

Apr 15, 2025

Neuroscientific to Acquire Leading Stem Cell Technology - Investing News Network

Apr 15, 2025

Apr 14, 2025

American Century Companies Inc. Boosts Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Apr 14, 2025

Apr 11, 2025

Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace

Apr 11, 2025

Apr 07, 2025

Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $6.67 - Defense World

Apr 07, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Has $1.26 Million Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Mar 30, 2025

Mar 29, 2025

2seventy bio, Inc. (NASDAQ:TSVT) Shares Acquired by Intech Investment Management LLC - The AM Reporter

Mar 29, 2025

Mar 28, 2025

Bluebird gets rival takeout offer from Ayrmid - BioPharma Dive

Mar 28, 2025

Mar 25, 2025

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Mar 25, 2025

Mar 13, 2025

Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma

Mar 13, 2025

Mar 13, 2025

2seventy bio, Inc. (NASDAQ:TSVT) Receives $7.20 Consensus PT from Analysts - Defense World

Mar 13, 2025

Mar 11, 2025

TSVT Up on Acquisition Agreement With BMY for $286 Million - Yahoo Finance

Mar 11, 2025

Mar 10, 2025

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire

Mar 10, 2025

Mar 10, 2025

Rhumbline Advisers Has $249,000 Holdings in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World

Mar 10, 2025

Mar 06, 2025

2Seventy Bio at TD Cowen Conference: Strategic Growth and Challenges - Investing.com

Mar 06, 2025

Feb 16, 2025

Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20 - Defense World

Feb 16, 2025

Feb 06, 2025

2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire

Feb 06, 2025

Feb 05, 2025

Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH - Managed Healthcare Executive

Feb 05, 2025

Jan 20, 2025

Weiss Ratings Reaffirms “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT) - Defense World

Jan 20, 2025